報價延遲最少15分鐘:2025/05/28 12:42 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.285 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
--/-3.60
|
|
企業價值
40.54M
|
| 資產負債 |
|
每股賬面淨值
0.68
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/28 12:42 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate. |